CTI Clinical Trial and Consulting, headquartered in Covington, has announced its participation in the Alliance for Regenerative Medicine (ARM)’s Cell and Gene Meeting on the Mediterranean, taking place April 28-30, in Rome, Italy.
The meeting brings together industry leaders across cell and gene therapy to share insights and discuss strategies shaping the future of advanced therapies.
CTI is a long-standing ARM partner and one of the earliest research organizations to join the association. With more than two decades of experience in cell and gene therapy, CTI has supported programs across the full development lifecycle and contributed to over half of currently approved FDA and EMA cell and gene therapy products.
During the conference, Dr. Monica Rodriguez, PhD, managing director of global laboratory, pharmacometrics, and site services at CTI, will moderate a roundtable session titled Removing Barriers in Cell and Gene Therapy: An Integrated Development Approach.
The session will take place on April 29 and will focus on how integrated scientific, clinical, and regulatory strategies can drive more efficient, regulatory-ready development programs.
To learn more about CTI’s capabilities in CGT, visit www.ctifacts.com.
CTI Clinical Trial and Consulting